SCL-1

SCL-1 is an orally active anti-PD-1/PD-L1 inhibitor that disrupts the interaction between PD-1 and PD-L1. It enhances the numbers of T cells, B cells, and natural killer cells. SCL-1 exhibits potent tumor growth inhibitory effects by inducing effector T cells within the tumor and upregulating the expression of long non-coding RNAs as neoantigens, thereby activating cytotoxic T lymphocytes. SCL-1 is applicable in cancer research, including studies on triple-negative breast cancer.